- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:18 | Achari Ventures I Extends Deadline, Secures up to $350K From Merger Partner Vaso | 1 | The SPAC Conference | ||
| 10.04. | Achari Ventures I Files Proxy on $176M Vaso Deal | 1 | The SPAC Conference | ||
| 01.04. | Vasomedical reports Q4 results | 1 | Seeking Alpha | ||
| 01.04. | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2023 | 48 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO) today announced its operating results for the three months and year ended December 31, 2023. "The Company... ► Artikel lesen | |
| 01.04. | VASO Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 21.02. | Should You Hold Vaso Corporation (VASO)? | 1 | Insider Monkey | ||
| 08.12.23 | MedTech Co. Vaso Combining with Achari Ventures Holdings I in $176M Deal | 2 | The SPAC Conference | ||
| 08.12.23 | Vaso Corporation set to merge with Achari Ventures, uplist to Nasdaq | 1 | Investing.com | ||
| 08.12.23 | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
| 07.12.23 | Vaso to list on Nasdaq via SPAC merger | 1 | Seeking Alpha | ||
| 07.12.23 | Vaso Corporation, a Diversified Medical Technology Company Currently Trading on the OTCQX Market, to List on Nasdaq via SPAC Merger | 499 | ACCESSWIRE | Business Combination with Achari Ventures Holdings Corp. I is Expected to Be Completed in First Quarter of 2024Merger with Achari Ventures Holdings Corp. I (NASDAQ:AVHI) expected to improve capital... ► Artikel lesen | |
| 14.11.23 | Vasomedical reports Q3 results | 1 | Seeking Alpha | ||
| 14.11.23 | Vaso Corporation Announces Financial Results for Third Quarter 2023 | 310 | ACCESSWIRE | Making it the sixth consecutive quarter of profitabilityPLAINVIEW, NY / ACCESSWIRE / November 14, 2023 / Vaso Corporation ("Vaso") (OTCQX:VASO) today reported its operating results for the three months... ► Artikel lesen | |
| 25.09.23 | Vaso Corporation Announces Upgrade to OTCQX Best Market from OTCQB Venture Market | 383 | ACCESSWIRE | PLAINVIEW, NY / ACCESSWIRE / September 25, 2023 / Vaso Corporation ("Vaso") (OTCQB:VASO) today announced that its application to trade on the OTCQX Best Market has been approved by OTC Markets Group... ► Artikel lesen | |
| 14.08.23 | Vaso Corporation Announces Financial Results for Second Quarter 2023 | 343 | ACCESSWIRE | Company reports continued growth in revenue and record profitabilityPLAINVIEW, NY / ACCESSWIRE / August 14, 2023 / Vaso Corporation ("Vaso") (OTCQB:VASO) today reported its operating results for the... ► Artikel lesen | |
| 15.05.23 | Vaso Corporation Announces Financial Results for First Quarter 2023 | 311 | ACCESSWIRE | Revenue and Profitability Continued to Improve Year-over-yearPLAINVIEW, NY / ACCESSWIRE / May 15, 2023 / Vaso Corporation ("Vaso") (OTCQB:VASO) today reported its operating results for the three months... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 26,895 | -0,28 % | Bayer-Aktie oder Vonovia-Aktie: Bei welchem DAX-Konzern ist ein Turnaround wahrscheinlicher? | Sowohl Bayer als auch Vonovia sind zuletzt arg unter Druck geraten und stecken in einem Turnaround. Doch welcher der beiden Werte hat die besseren Chancen, wieder zu alten Hochs zurückzufinden? Mit... ► Artikel lesen | |
| ASTRAZENECA | 141,15 | +6,45 % | Ihre wichtigsten Termine: Frische Q1-Zahlen von: Alphabet, Snap, Intel, AstraZeneca, Hermes und Nestle | © Foto: Rolf Vennenbernd/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:30... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 15,310 | -0,58 % | Veru, EyePoint Pharmaceuticals, SINTX Technologies among healthcare movers | ||
| SANOCHEMIA PHARMAZEUTIKA | - | - | Nachlese: Magnus Brunner vs. FMA" EOSS holt nach Sanochemia auch BDI BioEnergy; Bettina Pfluger (Christian Drastil) | Um 12:12 liegt der ATX mit +0.03 Prozent im Plus bei 3452 Punkten (Ultimo 2023: 3435, 0.49% ytd). Topperformer der PIR-Group sind Addiko Bank mit +1.82% auf 15.425 Euro, dahinter DO&CO mit +1.79% auf... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 39,410 | -0,66 % | Ionis Pharmaceuticals, Inc.: Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome | - Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events -
-... ► Artikel lesen | |
| CSPC PHARMA | 0,751 | +3,70 % | CSPC Pharmaceutical Group-Aktie kann Vortagsniveau nicht halten (0,686 €) | Im Minus liegt zur Stunde die Aktie der CSPC Pharmaceutical Group . Das Wertpapier kostete zuletzt 0,69 Euro. An der Börse liegt die CSPC Pharmaceutical Group-Aktie aktuell im Minus. Die Aktie verbilligte... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 15,540 | +0,32 % | Aktien New York: Indizes bauen Gewinne aus - Inflationsdaten im Fokus | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben nach einem trägen Wochenstart am Dienstag zugelegt. Allerdings reagierten die Aktienkurse erst mit einiger Verzögerung positiv auf US-Inflationsdaten... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,418 | -1,12 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update | Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified Biomarkers... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 180,15 | -5,73 % | Madrigal Pharmaceuticals, Inc.: Madrigal Statement on the Passing of Dr. Stephen Harrison | ||
| CATALYST PHARMACEUTICALS | 13,855 | -1,98 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 | ||
| OCUPHIRE PHARMA | 1,448 | +1,54 % | Ocuphire Pharma: First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery | LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP)... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,056 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 17.11.2023 | The following instruments on Boerse Frankfurt do have their last trading day on 17.11.2023Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 17.11.2023ISIN NameAU000000DCN6 DACIAN... ► Artikel lesen | |
| DMK PHARMACEUTICALS | 0,049 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 2 | The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameLU0102219945 G.SACHS... ► Artikel lesen | |
| CHUGAI PHARMACEUTICAL | 29,280 | -2,40 % | Chugai Pharmaceutical reports Q1 results | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information | Conference Call Scheduled for Thursday, February 15 at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pharmaceutical... ► Artikel lesen |
VASO CORPORATION gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
